Quince Therapeutics, Inc. (QNCX) Earnings Call Transcripts

Quince Therapeutics, Inc.'s Latest Earnings Call - June 11, 2026

During the Quince Therapeutics Annual Meeting held on June 11, 2026, the company announced the approval of a reverse stock split ranging from 1:10 to 1:100, which could significantly impact share liquidity and market perception. The meeting also confirmed the election of June Bray to the Board of Directors and ratified the selection of BDO USA as the independent auditor for the fiscal year ending December 31, 2026. Specific financial metrics and earnings guidance were not disclosed in this meeting, leaving investors awaiting further updates.

Reported metrics

Guidance from management

No specific financial guidance or earnings updates were provided during the meeting, leaving future performance metrics unclear.

What management said

I approve by affidavit certifying that notice of this meeting was duly given and that the notice of Annual Meeting of Stockholders was mailed on or about April 30, 2026, to all stockholders of record at the close of business on April 23, 2026, the record date for the meeting.

Thank you. We have appointed Jordan Hirsch, a representative of Equiniti Transfer Agent Services, to act as Inspector of Elections for this annual meeting. The Inspector of Elections has signed an oath of office, which will be filed with the minutes of this meeting. Will the Secretary please report at this time with respect to the existence of a quorum?

What analysts pressed on

Analysts expressed concerns regarding the implications of the reverse stock split on share price and market perception. There were also questions about the lack of financial performance metrics disclosed during the meeting, which could impact investor sentiment moving forward.

Main topics on the call

• Reverse Stock Split Approval — Management confirmed the approval of a reverse stock split of outstanding shares by a ratio between 1:10 and 1:100, stating, 'the exact ratio to be set within that range at the discretion of our Board of Directors.' This...
• Board of Directors Election — June Bray was elected as a Class I director to serve until the 2029 Annual Meeting, which signals stability in governance. Dirk Thye noted, 'June Bray has been elected as Class I director to serve until our 2029 Annual M...
• Independent Auditor Ratification — The selection of BDO USA as the independent auditor for the fiscal year ending December 31, 2026, was ratified, indicating continuity in financial oversight. This was confirmed during the meeting without any dissent.
• Compensation Advisory Vote — The advisory vote on the compensation of named executive officers was approved, reflecting shareholder support for management's compensation strategy. This was disclosed in the proxy statement prior to the meeting.

Read the full Quince Therapeutics, Inc. transcript (June 11, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 18 Quince Therapeutics, Inc. earnings call transcripts on record, spanning March 16, 2021 to June 11, 2026. Based on this history, Quince Therapeutics, Inc. reports quarterly. The most recent call on file is dated June 11, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

QNCX

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

18

First call

March 16, 2021

Most recent

June 11, 2026

Reporting cadence

quarterly